Table 1 Baseline characteristics in patients with IPAH and healthy controls

Age, years

46.1 ± 17.6

48.3 ± 14.3

Male/Female, n

14/27

20/30

Nonsurvivors, n

12

0

BMI, kg/m²

22.8 ± 4.4

–

NT-proBNP, pg/mL

797 (296–3035)

–

WHO-FC III/IV, n (%)

25 (59.2)

–

6MWD, m

362.2 ± 109.7

–

mRAP, mmHg

6.0 ± 5.1

–

mPAP, mmHg

56.2 ± 18.6

–

mPAWP, mmHg

8.3 ± 4.0

–

PVR, Wood units

15.8 ± 13.5

–

CO, L/min

3.5 ± 1.4

–

Specific therapy, n (%)

PDE-5 inhibitors

10 (24.4)

–

ERAs

10 (24.4)

–

sGC stimulator

2 (4.9)

–

Combination

19 (46.3)

–